Heike Luise Pahl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heike Luise Pahl has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Albert Gründer
Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Germany
2 shared publicationsElisabeth Strunck
From the Department of Experimental Anaesthesiology, University Hospital Freiburg, Center for Tumor Biology, Freiburg, Germany; the Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany; the Center for Tumor Biology, Freiburg, Germany; the Department of Hematology/Oncology, University Hospital Munich, Munich, Germany; and the Department of Pathology, University Hospital Freiburg, Freiburg, Germany
2 shared publicationsGerold Meinhardt
From the Department of Experimental Anaesthesiology, University Hospital Freiburg, Center for Tumor Biology, Freiburg, Germany; the Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany; the Center for Tumor Biology, Freiburg, Germany; the Department of Hematology/Oncology, University Hospital Munich, Munich, Germany; and the Department of Pathology, University Hospital Freiburg, Freiburg, Germany
2 shared publicationsHans-Eckart Schaefer
From the Department of Experimental Anaesthesiology, University Hospital Freiburg, Center for Tumor Biology, Freiburg, Germany; the Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany; the Center for Tumor Biology, Freiburg, Germany; the Department of Hematology/Oncology, University Hospital Munich, Munich, Germany; and the Department of Pathology, University Hospital Freiburg, Freiburg, Germany
2 shared publicationsJ. Wehrle
Division of Molecular Hematology, University Hospital Freiburg, Center for Clinical Research, Freiburg, Germany
2 shared publicationsMarc Azemar
From the Department of Experimental Anaesthesiology, University Hospital Freiburg, Center for Tumor Biology, Freiburg, Germany; the Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany; the Center for Tumor Biology, Freiburg, Germany; the Department of Hematology/Oncology, University Hospital Munich, Munich, Germany; and the Department of Pathology, University Hospital Freiburg, Freiburg, Germany
2 shared publications
Latest Publications
- Open Access
- 6 July 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 380-390
Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers. Patients ≥ 18 years with a diagnosis of PMF or PPV‐MF or PET‐MF, who were suitable for in‐label treatment with RUX were eligible and could be included either before (479 previously RUX‐naïve [Arm A]) or after the start of treatment (464 RUX‐experienced patients [Arm B]) and were followed over 36 months. Arm A showed rapid (≤ 6 months), sustained improvements from baseline in all efficacy outcomes and most QOL measures. Both arms showed an ~17% increase in the proportion of patients experiencing a normal German QOL during follow‐up. Arm B entered the study with better outcomes and QOL than Arm A, with outcomes generally remaining stable over time. Adverse events were less common than in registrational trials, possibly due, in part, to lower real‐world RUX dosing. Survival was comparable to published data. The JAKoMo study demonstrates that real‐world RUX treatment of MF promotes significant and sustained clinical and QOL benefits, including improvement of general health and alleviation of MF‐associated fatigue. Maximum sustained responses were generally achieved within 6 months and associated with fewer adverse events than in published randomized trials, which may reflect more conservative and personalized real‐world dosing.Trial Registration: The JAKOMO trial: http://clinicaltrials.gov/show/NCT05044026
- 6 July 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 380-390
Open AccessFinal Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers. Patients ≥ 18 years with a diagnosis of PMF or PPV‐MF or PET‐MF, who were suitable for in‐label treatment with RUX were eligible and could be included either before (479 previously RUX‐naïve [Arm A]) or after the start of treatment (464 RUX‐experienced patients [Arm B]) and were followed over 36 months. Arm A showed rapid (≤ 6 months), sustained improvements from baseline in all efficacy outcomes and most QOL measures. Both arms showed an ~17% increase in the proportion of patients experiencing a normal German QOL during follow‐up. Arm B entered the study with better outcomes and QOL than Arm A, with outcomes generally remaining stable over time. Adverse events were less common than in registrational trials, possibly due, in part, to lower real‐world RUX dosing. Survival was comparable to published data. The JAKoMo study demonstrates that real‐world RUX treatment of MF promotes significant and sustained clinical and QOL benefits, including improvement of general health and alleviation of MF‐associated fatigue. Maximum sustained responses were generally achieved within 6 months and associated with fewer adverse events than in published randomized trials, which may reflect more conservative and personalized real‐world dosing.Trial Registration: The JAKOMO trial: http://clinicaltrials.gov/show/NCT05044026
- Open Access
- 30 April 2021
- Published by Wiley in HemaSphere
- Vol. 5 (5) , e565
Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models
Even after development of the JAK1/JAK2 inhibitor ruxolitinib, myeloproliferative neoplasm (MPN) patients require novel therapeutic options. While ruxolitinib can considerably improve quality of life and prolong survival, it does not modify the natural disease course in most patients. Moreover, resistance develops with prolonged use. Therefore, various combination treatments are currently being investigated. Published data provide a compelling rationale for the inhibition of insulin growth factor-1 receptor (IGF-1R) signaling in MPN. Here we report that genetic and pharmacological inhibition of IGF-1R selectively reduced Jak2V617F-driven cytokine-independent proliferation ex vivo. Two different structurally unrelated IGF-1R inhibitors ameliorated disease phenotype in a murine MPN model and significantly prolonged survival. Moreover, in mice, low-dose ruxolitinib synergized with IGF-1R inhibition to increase survival. Our data demonstrate preclinical efficacy of IGF-1R inhibition in a murine MPN model.
- 30 April 2021
- Published by Wiley in HemaSphere
- Vol. 5 (5) , e565
Open AccessPharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models
Even after development of the JAK1/JAK2 inhibitor ruxolitinib, myeloproliferative neoplasm (MPN) patients require novel therapeutic options. While ruxolitinib can considerably improve quality of life and prolong survival, it does not modify the natural disease course in most patients. Moreover, resistance develops with prolonged use. Therefore, various combination treatments are currently being investigated. Published data provide a compelling rationale for the inhibition of insulin growth factor-1 receptor (IGF-1R) signaling in MPN. Here we report that genetic and pharmacological inhibition of IGF-1R selectively reduced Jak2V617F-driven cytokine-independent proliferation ex vivo. Two different structurally unrelated IGF-1R inhibitors ameliorated disease phenotype in a murine MPN model and significantly prolonged survival. Moreover, in mice, low-dose ruxolitinib synergized with IGF-1R inhibition to increase survival. Our data demonstrate preclinical efficacy of IGF-1R inhibition in a murine MPN model.
- Open Access
- 18 June 2020
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (4) , 1158-1162
Concomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia
- 18 June 2020
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (4) , 1158-1162
Open AccessConcomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia
- Open Access
- 1 January 2015
- Published by Wiley in Mediators of Inflammation
- Vol. 2015 (1) , 101987
The Hen or the Egg: Inflammatory Aspects of Murine MPN Models
It has been known for some time that solid tumors, especially gastrointestinal tumors, can arise on the basis of chronic inflammation. However, the role of inflammation in the genesis of hematological malignancies has not been extensively studied. Recent evidence clearly shows that changes in the bone marrow niche can suffice to induce myeloid diseases. Nonetheless, while it has been demonstrated that myeloproliferative neoplasms (MPN) are associated with a proinflammatory state, it is not clear whether inflammatory processes contribute to the induction or maintenance of MPN. More provocatively stated: which comes first, the hen or the egg, inflammation or MPN? In other words, can chronic inflammation itself trigger an MPN? In this review, we will describe the evidence supporting a role for inflammation in initiating and promoting MPN development. Furthermore, we will compare and contrast the data obtained in gastrointestinal tumors with observations in MPN patients and models, pointing out the opportunities provided by novel murine MPN models to address fundamental questions regarding the role of inflammatory stimuli in the molecular pathogenesis of MPN.
- 1 January 2015
- Published by Wiley in Mediators of Inflammation
- Vol. 2015 (1) , 101987
Open AccessThe Hen or the Egg: Inflammatory Aspects of Murine MPN Models
It has been known for some time that solid tumors, especially gastrointestinal tumors, can arise on the basis of chronic inflammation. However, the role of inflammation in the genesis of hematological malignancies has not been extensively studied. Recent evidence clearly shows that changes in the bone marrow niche can suffice to induce myeloid diseases. Nonetheless, while it has been demonstrated that myeloproliferative neoplasms (MPN) are associated with a proinflammatory state, it is not clear whether inflammatory processes contribute to the induction or maintenance of MPN. More provocatively stated: which comes first, the hen or the egg, inflammation or MPN? In other words, can chronic inflammation itself trigger an MPN? In this review, we will describe the evidence supporting a role for inflammation in initiating and promoting MPN development. Furthermore, we will compare and contrast the data obtained in gastrointestinal tumors with observations in MPN patients and models, pointing out the opportunities provided by novel murine MPN models to address fundamental questions regarding the role of inflammatory stimuli in the molecular pathogenesis of MPN.
- Open Access
- 20 June 2014
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (10) , e208-e210
NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway
- 20 June 2014
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (10) , e208-e210
Open AccessNFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway
- 26 February 2013
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (7) , 1073-1080
Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms
The transcription factor nuclear factor erythroid-2 is over-expressed in patients with myeloproliferative neoplasms irrespective of the presence of the JAK2(V617F) mutation. Our transgenic mouse model over-expressing nuclear factor erythroid-2, which recapitulates many features of myeloproliferative neoplasms including transformation to acute myeloid leukemia, clearly implicates this transcription factor in the pathophysiology of myeloproliferative neoplasms. Because the targets mediating nuclear factor erythroid-2 effects are not well characterized, we conducted microarray analysis of CD34(+) cells lentivirally transduced to over-express nuclear factor erythroid-2 or to silence this transcription factor via shRNA, in order to identify novel target genes. Here, we report that the cytokine interleukin 8 is a novel target gene. Nuclear factor erythroid-2 directly binds the interleukin 8 promoter in vivo, and these binding sites are required for promoter activity. Serum levels of interleukin 8 are known to be elevated in both polycythemia vera and primary myelofibrosis patients. Recently, increased interleukin 8 levels have been shown to be predictive of inferior survival in primary myelofibrosis patients in multivariate analysis. Therefore, one of the mechanisms by which nuclear factor erythroid-2 contributes to myeloproliferative neoplasm pathology may be increased interleukin 8 expression.
- 26 February 2013
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (7) , 1073-1080
Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms
The transcription factor nuclear factor erythroid-2 is over-expressed in patients with myeloproliferative neoplasms irrespective of the presence of the JAK2(V617F) mutation. Our transgenic mouse model over-expressing nuclear factor erythroid-2, which recapitulates many features of myeloproliferative neoplasms including transformation to acute myeloid leukemia, clearly implicates this transcription factor in the pathophysiology of myeloproliferative neoplasms. Because the targets mediating nuclear factor erythroid-2 effects are not well characterized, we conducted microarray analysis of CD34(+) cells lentivirally transduced to over-express nuclear factor erythroid-2 or to silence this transcription factor via shRNA, in order to identify novel target genes. Here, we report that the cytokine interleukin 8 is a novel target gene. Nuclear factor erythroid-2 directly binds the interleukin 8 promoter in vivo, and these binding sites are required for promoter activity. Serum levels of interleukin 8 are known to be elevated in both polycythemia vera and primary myelofibrosis patients. Recently, increased interleukin 8 levels have been shown to be predictive of inferior survival in primary myelofibrosis patients in multivariate analysis. Therefore, one of the mechanisms by which nuclear factor erythroid-2 contributes to myeloproliferative neoplasm pathology may be increased interleukin 8 expression.
- 1 November 2007
- Published by Elsevier in Experimental Hematology
- Vol. 35 (11) , 1695-1703
JAK2-negative ET patients do not display constitutively active JAK/STAT signaling
- 1 November 2007
- Published by Elsevier in Experimental Hematology
- Vol. 35 (11) , 1695-1703
JAK2-negative ET patients do not display constitutively active JAK/STAT signaling
- 31 October 2005
- Published by Elsevier in Seminars in Hematology
- Vol. 42 (4) , 196-205
Chromosomal Abnormalities and Molecular Markers in Myeloproliferative Disorders
- 31 October 2005
- Published by Elsevier in Seminars in Hematology
- Vol. 42 (4) , 196-205
Chromosomal Abnormalities and Molecular Markers in Myeloproliferative Disorders
- 1 July 2004
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 4 (4) , 495-502
Diagnostic approaches to polycythemia vera in 2004
Four years have passed since publication of the latest update in clinical criteria for the diagnosis of polycythemia vera. During this time, the first molecular markers for polycythemia vera have been described. They include decreased expression of the thrombopoietin receptor, c-Mpl, and overexpression of the polycythemia rubra vera-1 messenger RNA. These biomarkers, which are not in themselves the causative changes leading to disease development but nonetheless appear intricately linked to the pathological process, may constitute a useful addition to our diagnostic repertoire. This review examines both the currently available clinical criteria and the possible role of biomarkers in the diagnosis of polycythemia vera. From this discussion, a refined set of diagnostic criteria for polycythemia vera is proposed.
- 1 July 2004
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 4 (4) , 495-502
Diagnostic approaches to polycythemia vera in 2004
Four years have passed since publication of the latest update in clinical criteria for the diagnosis of polycythemia vera. During this time, the first molecular markers for polycythemia vera have been described. They include decreased expression of the thrombopoietin receptor, c-Mpl, and overexpression of the polycythemia rubra vera-1 messenger RNA. These biomarkers, which are not in themselves the causative changes leading to disease development but nonetheless appear intricately linked to the pathological process, may constitute a useful addition to our diagnostic repertoire. This review examines both the currently available clinical criteria and the possible role of biomarkers in the diagnosis of polycythemia vera. From this discussion, a refined set of diagnostic criteria for polycythemia vera is proposed.
- 1 August 2003
- Published by Taylor & Francis in Hematology
- Vol. 8 (4) , 199-209
Molecular Markers in Myeloproliferative Disorders: From Classification to Prognosis?
The recent description of molecular markers in patients with myeloproliferative disorders (MPDs) has raised several questions: does the presence of multiple markers coincide in individual patients or can a patient acquire some markers selectively? Do the markers distinguish molecular categories of MPDs? Do these categories coincide with the clinically defined subgroups of MPDs: PV, ET and IMF? If not, which system of categorization is more useful to the patient and his physician, the molecular one or the clinical one, and why? The present review will summarize the current knowledge of molecular markers in MPDs and discuss today's answers to the above questions. Since our knowledge of the molecular basis of MPDs is rapidly expanding, it is my hope that this review will soon be outdated.
- 1 August 2003
- Published by Taylor & Francis in Hematology
- Vol. 8 (4) , 199-209
Molecular Markers in Myeloproliferative Disorders: From Classification to Prognosis?
The recent description of molecular markers in patients with myeloproliferative disorders (MPDs) has raised several questions: does the presence of multiple markers coincide in individual patients or can a patient acquire some markers selectively? Do the markers distinguish molecular categories of MPDs? Do these categories coincide with the clinically defined subgroups of MPDs: PV, ET and IMF? If not, which system of categorization is more useful to the patient and his physician, the molecular one or the clinical one, and why? The present review will summarize the current knowledge of molecular markers in MPDs and discuss today's answers to the above questions. Since our knowledge of the molecular basis of MPDs is rapidly expanding, it is my hope that this review will soon be outdated.